Actively Recruiting
Evaluating 68GaGa DOTA-5G PETCT Imaging for Detecting Metastatic or Advanced Invasive Lobular Breast Cancer
Led by University of California, Davis · Updated on 2026-09-14
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new diagnostic imaging agent called 68GaGa DOTA-5G in patients with metastatic or advanced invasive lobular breast cancer LBC. This phase I study aims to determine if 68GaGa DOTA-5G can detect cancer lesions more sensitively than the current standard 18F-FDG PETCT, while also assessing its safety and tolerability. The study plans to enroll 30 patients over 24 months to gather initial data on this imaging approach. Participants will receive an injection of up to 5 mCi of 68GaGa DOTA-5G and undergo PETCT scans at 1 and 2 hours after injection. This imaging process is designed to highlight cancer lesions for evaluation. The study is a single-group design without placebo or comparator arms, focusing on assessing the agents diagnostic capabilities and safety profile. During the study, participants will be monitored for the ability of the imaging to detect lesions within 2 hours of injection and for any adverse events occurring up to 7 days post-injection, using standard safety criteria. Patients must remain still for 30 to 60 minutes during scans. The total participation involves screening, imaging, and follow-up for safety, with the study concluding by June 2027.
CONDITIONS
Brief Title
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Research Team
J
Julie Sutcliffe, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here